Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by SMARCA2 is a member of the SWI/SNF family of proteins and is highly similar to the brahma protein of Drosophila. Additionally we are shipping SMARCA2 Proteins (5) and many more products for this protein.
Showing 10 out of 50 products:
Human Polyclonal SMARCA2 Primary Antibody for ICC, IF - ABIN4285267
Van Houdt, Nowakowska, Sousa, van Schaik, Seuntjens, Avonce, Sifrim, Abdul-Rahman, van den Boogaard, Bottani, Castori, Cormier-Daire, Deardorff, Filges, Fryer, Fryns, Gana, Garavelli et al.: Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome. ... in Nature genetics 2012
Show all 2 Pubmed References
Human Monoclonal SMARCA2 Primary Antibody for ChIP, ICC - ABIN2668505
Okada, Harada, Saiwai, Nakamura, Ohkawa: Generation of a rat monoclonal antibody specific for Brm. in Hybridoma (2005) 2009
at genes where BRG1 (show SMARCA4 Antibodies) and BRM antagonize one another we observe a nearly complete rescue of gene expression changes in the combined BRG/BRM double knockdown
Expression of BRM and MMP2 (show MMP2 Antibodies) in the thoracic aortic aneurysm and aortic dissection is very high, indicating that BRM and MMP2 (show MMP2 Antibodies) may play important roles in the occurrence and development of thoracic aortic aneurysm and aortic dissection.
Although Genome-Wide Association studies have not been carried out in the field of alcohol-related hepatocellular carcinoma (HCC (show FAM126A Antibodies)), common single nucleotide polymorphisms conferring a small increase in the risk of liver cancer risk have been identified. Specific patterns of gene mutations including CTNNB1 (show CTNNB1 Antibodies), TERT (show TERT Antibodies), ARID1A (show ARID1A Antibodies) and SMARCA2 exist in alcohol-related HCC (show FAM126A Antibodies). [review]
PRC2-mediated repression of SMARCA2 predicts EZH2 (show EZH2 Antibodies) inhibitor activity in SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) mutant tumors.
two promoter BRM germline variants were associated with worse outcome in our esophageal adenocarcinoma (EAC (show CYLD Antibodies)) patients. This significantly poorer outcome was independent of TNM (show ODZ1 Antibodies) classification at diagnosis or other clinic-demographic variables.
Epigenetic regulatory molecules bind to two BRM promoter sequence variants but not to their wild-type sequences. These variants are associated with adverse overall and progression-free survival. Decreased BRM gene expression, seen with these variants, is also associated with worse overall survival
We also demonstrate that tazemetostat, a potent and selective EZH2 (show EZH2 Antibodies) inhibitor currently in phase II clinical trials, induces potent antiproliferative and antitumor effects in SCCOHT cell lines and xenografts deficient in both SMARCA2 and SMARCA4 (show SMARCA4 Antibodies). These results exemplify an additional class of rhabdoid-like tumors that are dependent on EZH2 (show EZH2 Antibodies) activity for survival.
Two BRM promoter polymorphisms were strongly associated with hepatocellular carcinoma (HCC (show FAM126A Antibodies)) prognosis but were not associated with increased HCC (show FAM126A Antibodies) susceptibility.
This de novo SMARCA2 missense mutation c.3721C>G, p.Gln1241Glu is the only reported mutation on exon 26 outside the ATPase (show DNAH8 Antibodies) domain of SMARCA2 to be associated with Nicolaides-Baraitser syndrome and adds to chromatin remodeling as a pathway for epileptogenesis.
We conclude that their features better resemble Coffin-Siris syndrome, rather than Nicolaides-Baraitser syndrome and that these features likely arise from SMARCA2 over-dosage. Pure 9p duplications (not caused by unbalanced translocations) are rare. Copy number analysis in patients with features that overlap with Coffin-Siris syndrome is recommended to further determine their genetic aspects.
BRG1 (show SMARCA4 Antibodies)/BRM and c-MYC (show MYC Antibodies) have an antagonistic relationship regulating the expression of cardiac conduction genes that maintain contractility, which is reminiscent of their antagonistic roles as a tumor suppressor and oncogene (show RAB1A Antibodies) in cancer.
SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) chromatin remodeler subunits Brg1 (show SMARCA4 Antibodies) and Brm are expressed differentially during drug-induced liver injury and regeneration in a mouse model.
these findings described a role for BRG1 (show SMARCA4 Antibodies) and BRM in mitochondrial quality control, by regulating mitochondrial number, mitophagy, and mitochondrial dynamics not previously recognized in the adult cardiomyocyte
BRM depletion enhances the proportion of cells expressing markers of osteoblast precursors at the expense of cells able to differentiate along the adipocyte lineage.
Data show that knockdown of component of chromatin remodeling complex Brm or Baf170 (show SMARCC2 Antibodies) at different stages promotes reprogramming.
Data reveal stage-specific roles of Brm during skeletal myogenesis, via formation of repressive and activatory SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) complexes.
Brm protects from UV-induced hyperplastic growth in both cutaneous and corneal keratinocytes
Data suggest that Brg1 (show SMARCA4 Antibodies) and Brm integrate various proinflammatory cues into cell adhesion molecule (show MCAM Antibodies) transactivation in endothelial injury.
A SMARCA2-containing residual SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) complex underlies the oncogenic activity of SMARCA4 (show SMARCA4 Antibodies) mutant cancers.
The protein encoded by this gene is a member of the SWI/SNF family of proteins and is highly similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. Two transcript variants encoding different isoforms have been found for this gene, which contains a trinucleotide repeat (CAG) length polymorphism.
ATP-dependent helicase SMARCA2
, BRG1-associated factor 190B
, SNF2/SWI2-like protein 2
, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a2
, global transcription activator homologous sequence
, probable global transcription activator SNF2L2
, protein brahma homolog
, sucrose nonfermenting 2-like protein 2
, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2
, subunit of the SWI/SNF chromatin remodeling complex
, phasmid Socket Absent PSA-4